Guardian Pharmacy Services, Inc.

NYSE:GRDN

Medical - Distribution

Healthcare
$48.84 +0.39%

+$0.17 today

Market cap
$3.09B
Beta
0.08
P/E (TTM)
52.0
EPS (TTM)
$0.84
52W Low $19.30High $44.00

Volume 0.45M

Average 0.48M

GRDN Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Guardian Pharmacy Services, Inc.NYSE: GRDN

Accounts Receivables · Q2 FY2026 · quarter ended Jun 2026

Accounts receivables growth accelerates

Q2 FY2026 accounts receivables of $6.25M rose 140.8% year over year, ahead of the +71.7% change in trailing-twelve-month accounts receivables. Over 3 fiscal years it compounded at -20.1% a year.

Context

  • Accounts receivables amounted to 0.6% of revenue in FY2025, down 1.5 pp from a year earlier.
  • Accounts receivables grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +140.8% holds above the trailing-twelve-month pace of +71.7%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$6.25M+156.1% QoQ
Last fiscal yearDec 2025
-$8.55M-66.4% YoY
LTMJun 2026
-$15.02M+71.7% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+140.8%——
1 year-66.4%——
3-year CAGR-20.1%——
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
(8.55M) USD
Year-over-year change
+66.4%

Accounts Receivables vs competitors

How GRDN compares with its peers on the latest reported figures

  • GRDN's LTM Jun 2026 accounts receivables of $15.02M is the 5th largest of the 11 companies compared; the peer median is $8.4M.
  • Its year-over-year change of +71.7% is the 6th highest of 10, against a peer median of +249.5%.
  • Accounts receivables amounts to 1.0% of revenue for GRDN, versus a peer median of 5.6%.
GRDN Competitors Peer median
Accounts Receivables for GRDN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TXG10x Genomics, Inc.LTM Jun 2026$68.62M +351.8%—11.1%
QDELQuidelOrtho CorporationLTM Mar 2026$65.7M +249.5%—2.5%
JANXJanux Therapeutics, Inc.LTM Mar 2026$35M +401.4%—161.9%
PRCTPROCEPT BioRobotics CorporationLTM Mar 2026$18.14M -25.4%-56.4%5.6%
GRDNGuardian Pharmacy Services, Inc.LTM Jun 2026$15.02M +71.7%-20.1%1.0%
TWSTTwist Bioscience CorporationLTM Sep 2026$13.8M -38.3%+47.3%3.0%
NUVBNuvation Bio Inc.LTM Jun 2026$9.62M +260.7%—5.7%
NHCNational HealthCare CorporationLTM Sep 2026$8.96M +344.5%-1.6%0.6%
MESOMesoblast LimitedLTM Jun 2026$7.18M -242.9%—6.0%
MDPediatrix Medical Group, Inc.LTM Sep 2026$696K -101.8%—0.0%
EWTXEdgewise Therapeutics, Inc.LTM Sep 2026$0 ———
Peer median (excluding GRDN) $8.4M+249.5%-1.6%5.6%

Competitors are the stored peer set for GRDN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income28.33M49.66M37.72M(71.03M)49.22M
Depreciation & Amortization16.53M16.56M18.23M19.77M22.34M
Deferred Income Tax00003.07M
Stock-Based Compensation13.03M(3.38M)(6.09M)131.49M13.85M
Change in Working Capital(1.47M)(18.72M)15.6M(29.41M)6.38M
Accounts Receivables(7.71M)(16.79M)(14.3M)(25.49M)(8.55M)
Inventory(240K)(8.12M)4.43M(1.15M)(877K)
Accounts Payables9.78M13.37M6.3M13.23M16.4M
Other Working Capital(3.3M)(7.17M)19.18M(16M)(586K)
Other Non-Cash Items2.08M4.4M5.35M7.14M5.43M
Operating Cash Flow58.5M48.52M70.82M57.96M100.29M
Capital Expenditures(9.28M)(16.77M)(14.56M)(16.37M)(19.58M)
Acquisitions (Net)(4.4M)(2M)(985K)(14.71M)0
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities535K874K2.1M671K(12.68M)
Investing Cash Flow(13.15M)(17.9M)(13.44M)(30.41M)(32.26M)
Debt Repayment(6.1M)(2.8M)(2.89M)(36.48M)(4.98M)
Common Stock Issued000119.78M27.45M
Common Stock Repurchased000(55.18M)(29.04M)
Dividends Paid(17.36M)(30.8M)(38.42M)(35.75M)0
Other Financing Activities(13.34M)(11.42M)(15.92M)(16.02M)(497K)
Financing Cash Flow(36.79M)(45.03M)(57.23M)(23.65M)(7.07M)
Effect of Forex Changes00000
Net Change in Cash8.56M(14.41M)145K3.91M60.96M
Free Cash Flow49.22M31.75M56.26M41.59M80.71M

Guardian Pharmacy Services, Inc.

NYSE:GRDN

Intrinsic Alpha fair value

Locked

Current Price

$48.84

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.